

CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181

DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

DELHI ABHA NO **NEW DELHI 110030**

RECEIVED: 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval** Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

XRAY-CHEST

8800465156

NO ABNORMALITY DETECTED **IMPRESSION**

ECG

INCOMPLATE RBBB. **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT

RELEVANT PAST HISTORY COVID IN 2020.HOME QUARANTINED.

JAUNDICE IN 2010.

MARRIED / MIXED DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL. RELEVANT PERSONAL HISTORY

RELEVANT FAMILY HISTORY **NOT SIGNIFICANT** HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

mts HEIGHT IN METERS 1.72 WEIGHT IN KGS. 85 Kgs BMI 29 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

NORMAL MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE

Page 1 Of 22





Thane, 400602 Maharashtra, India

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956





CODE/NAME & ADDRESS : C000138394 ACCESSION NO : **0181XD000828** AGE/SEX : 35 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

| CLIENT PATIENT ID: | RECEIVED : 17/04/2024 09:48:16 |
| REPORTED : 19/04/2024 15:04:20 |

Test Report Status Final Results Biological Reference Interval Units

GENERAL APPEARANCE / NUTRITIONAL HEALTHY

STATUS

8800465156

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL
NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL TEMPERATURE NORMAL

PULSE 74/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 110/70 MM HG mm/Hg

(SUPINE)

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST

MOVEMENTS OF CHEST

BREATH SOUNDS INTENSITY

NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

Page 2 Of 22





View Details

View Repor

Thane, 400602 Maharashtra, India

 $\mathsf{Tel} : 911159\overset{\cdot}{1}115, \, \mathsf{Fax} : \mathsf{CIN} - \mathsf{U74899PB1995PLC045956}$





CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181 DRAWN

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16

DELHI ABHA NO REPORTED :19/04/2024 15:04:20 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

PER ABDOMEN

8800465156

APPEARANCE NORMAL VENOUS PROMINENCE **ABSENT**

LIVER NOT PALPABLE **SPLEEN** NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS **NORMAL** CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL NORMAL** MOTOR SYSTEM **REFLEXES NORMAL**

MUSCULOSKELETAL SYSTEM

NORMAL SPINE NORMAL **JOINTS**

BASIC EYE EXAMINATION

CONJUNCTIVA **NORMAL NORMAL EYELIDS NORMAL** EYE MOVEMENTS **NORMAL CORNEA**

DISTANT VISION RIGHT EYE WITHOUT

GLASSES

DISTANT VISION LEFT EYE WITHOUT

GLASSES

WITHIN NORMAL LIMIT

WITHIN NORMAL LIMIT

Page 3 Of 22





View Report

S.K. Tower,Hari Niwas, Lbs Marg Thane, 400602

Maharashtra, India Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956





CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

: ANKIM130888181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16 **DELHI** ABHA NO REPORTED :19/04/2024 15:04:20 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

WITHIN NORMAL LIMIT NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT

NORMAL COLOUR VISION

SUMMARY

8800465156

RELEVANT HISTORY NOT SIGNIFICANT NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS

REMARKS / RECOMMENDATIONS LOW FAT, LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET. REGULAR EXERCISE.REGULAR WALK FOR 30-40 MIN DAILY.

REPEAT LIPID PROFILE, LDH AFTER 3 MONTHS OF DIET AND EXERCISE. WEIGHT LOSS:- LOW CALORIE, HIGH FIBRE DIET, REGULAR EXERCISE.

Page 4 Of 22





View Report

PERFORMED AT: Agilus Diagnostics Ltd S.K. Tower, Hari Niwas, Lbs Marg Thane, 400602

Maharashtra, India Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956





CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16 **DELHI** ABHA NO REPORTED :19/04/2024 15:04:20 **NEW DELHI 110030**

Test Report Status Results Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

GRADE I FATTY LIVER.

TMT OR ECHO

8800465156

CLINICAL PROFILE

NEGATIVE

Interpretation(s)

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Page 5 Of 22





View Report

S.K. Tower, Hari Niwas, Lbs Marg Thane, 400602

Maharashtra, India

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956



8800465156



PATIENT NAME: ANKIT PRATAP SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 AGE/SEX ACCESSION NO: 0181XD000828 :35 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 17/04/2024 09:48:16 DELHI REPORTED :19/04/2024 15:04:20 ABHA NO **NEW DELHI 110030**

Test Report Status Results Units **Final**

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 6 Of 22





S.K. Tower, Hari Niwas, Lbs Marg Thane, 400602 Maharashtra, India

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO : AGE/SEX :35 Years

WN :

RECEIVED : 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	LOW 40 MALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.3	13.0 - 17.0	g/dL	
METHOD : SLS- HEMOGLOBIN DETECTION METHOD	4 07	4.5 - 5.5	mil/µL	
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	4.87	4.5 - 5.5	IIIII/ µL	
WHITE BLOOD CELL (WBC) COUNT	7.59	4.0 - 10.0	thou/µL	
METHOD: FLUORESCENCE FLOW CYTOMETRY		.=		
PLATELET COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	167	150 - 410	thou/μL	
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	44.5	40.0 - 50.0	%	
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOLUME (MCV)	91.4	83.0 - 101.0	fL	
METHOD : CALCULATED FROM RBC & HCT	31.4	65.0 - 101.0	IL.	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.4	27.0 - 32.0	pg	
METHOD: CALCULATED FROM THE RBC & HGB	22.1	21 5 24 5	a /dl	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	32.1	31.5 - 34.5	g/dL	
METHOD: CALCULATED FROM THE HGB & HCT				
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE	13.5	11.6 - 14.0	%	
MENTZER INDEX	18.8			
MEAN PLATELET VOLUME (MPV)	13.1 High	6.8 - 10.9	fL	
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMA	ATOCRIT			
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	62	40 - 80	%	
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	26	20 40	%	
LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	26	20 - 40	70	
MONOCYTES	6	2 - 10	%	

Burgare

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 7 Of 22

View Details





Mumbai, 400078 Maharashtra, India

Fax: CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

AGE/SEX :35 Years

RECEIVED: 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

	<u> </u>	<u> </u>	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
EOSINOPHILS	5	1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
BASOPHILS	1	0 - 1	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	4.71	2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE LYMPHOCYTE COUNT	1.99	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE MONOCYTE COUNT	0.47	0.2 - 1.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE EOSINOPHIL COUNT	0.34	0.02 - 0.50	thou/μL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE BASOPHIL COUNT	0.08	0.02 - 0.10	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.4		

MORPHOLOGY

NORMOCYTIC NORMOCHROMIC RBC

NORMAL MORPHOLOGY **WBC**

METHOD: MICROSCOPIC EXAMINATION

ADEQUATE PLATELETS

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.(Mrs)Neelu K Bhojani **Lab Head**



Page 8 Of 22

View Report



Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax:







REF. DOCTOR: SELF **PATIENT NAME: ANKIT PRATAP SINGH**

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 17/04/2024 09:48:16

:35 Years

REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 0 - 14

METHOD: MODIFIED WESTERGREN

mm

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 4.6 Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

METHOD: HPLC

85.3 < 116.0 mg/dL ESTIMATED AVERAGE GLUCOSE(EAG)

METHOD: CALCULATED PARAMETER

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 9 Of 22

View Report



Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax:







REF. DOCTOR: SELF **PATIENT NAME: ANKIT PRATAP SINGH**

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

PATIENT ID : ANKIM130888181 DRAWN

CLIENT PATIENT ID: ABHA NO

RECEIVED: 17/04/2024 09:48:16

REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval Final** Units

REFERENCE :

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. ${\tt GLYCOSYLATED\ HEMOGLOBIN(HBA1C),\ EDTA\ WHOLE\ BLOOD-\textbf{Used\ For}:}$
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 10 Of 22

View Report



Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India







CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

Final

DELHI

NEW DELHI 110030

Test Report Status

8800465156

ACCESSION NO: 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:35 Years

Units

DRAWN

Biological Reference Interval

RECEIVED: 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

IMMUNOHAEMATOLOGY

Results

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE **POSITIVE**

METHOD: GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 11 Of 22









PATIENT NAME: ANKIT PRATAP SINGH

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

REF. DOCTOR: SELF

ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

RECEIVED: 17/04/2024 09:48:16

REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval** Units **Final**

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

Normal 75 - 99 FBS (FASTING BLOOD SUGAR) 80 mg/dL

Pre-diabetics: 100 - 125 Diabetic: > or = 126

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

METHOD: ENZYMATIC COLORIMETRIC ASSAY

PPBS(POST PRANDIAL BLOOD SUGAR) 88 70 - 139 mg/dL

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL 138 Desirable: < 200 mg/dL

Borderline: 200 - 239

High: > / = 240

TRIGLYCERIDES 114 Normal: < 150 mg/dL

Borderline high: 150 - 199

High: 200 - 499

Very High: >/= 500 METHOD: ENZYMATIC COLORIMETRIC ASSAY

31 Low HDL CHOLESTEROL At Risk: < 40 ma/dL

Desirable: > or = 60

METHOD: ENZYMATIC, COLORIMETRIC CHOLESTEROL LDL 84 Adult levels: mg/dL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

METHOD: ENZYMATIC COLORIMETRIC ASSAY

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Bhinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 12 Of 22





Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax:





8800465156





PATIENT NAME: ANKIT PRATAP SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16 DELHI REPORTED :19/04/2024 15:04:20 ABHA NO **NEW DELHI 110030**

		i i
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	107	Desirable: < 130 mg/dL Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220
VERY LOW DENSITY LIPOPROTEIN	22.8	< OR = 30.0 mg/dL
CHOL/HDL RATIO	4.5 High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0
LDL/HDL RATIO	2.7	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category		, ,	
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk		najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		betes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >1	90 mg/dl 5. Extreme of a single risk factor. 6. Coronary	
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	actors	
1. Age $>$ or $=$ 45 year	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			
	·	·	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Phinchkhede

Dr.Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 13 Of 22

Fax:







CODE/NAME & ADDRESS : C000138394 | ACCESSION NO : **0181XD000828** | AGE/SEX : 35 Years | Mal

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED : 17/04/2024 09:48:16

NEW DELHI 110030 ABHA NO : REPORTED :19/04/2024 15:04:20 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	$\langle OR = 30 \rangle$	< OR = 60)		
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.57	Upto 1.2	mg/dL
METHOD: COLORIMETRIC DIAZO			
BILIRUBIN, DIRECT	0.24	< 0.30	mg/dL
METHOD: DIAZO METHOD			
BILIRUBIN, INDIRECT	0.33	0.1 - 1.0	mg/dL
TOTAL PROTEIN	7.4	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD: COLORIMETRIC			
GLOBULIN	2.8	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	28	< OR = 50	U/L
METHOD: UV ABSORBANCE			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	40	< OR = 50	U/L
METHOD: UV ABSORBANCE			
ALKALINE PHOSPHATASE	69	40 - 129	U/L
METHOD: COLORIMETRIC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	19	0 - 60	U/L
METHOD : ENZYMATIC, COLORIMETRIC			
LACTATE DEHYDROGENASE	275 High	125 - 220	U/L
METHOD: UV ABSORBANCE			

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 8 6 - 20 mg/dL

METHOD: ENZYMATIC ASSAY

Dr. Ushma Wartikar, MD Consultant Pathologist Bhinchkhede.

Dr.Priyal Chinchkhede, MD Consultant Pathologist Angani

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 14 Of 22



View Report

Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India







CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

CREATININE, SERUM

BUN/CREAT RATIO

ACCESSION NO: 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:35 Years Male

RECEIVED: 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

Test Report Status	Final	Results Biological Reference Interval	Units
--------------------	-------	---------------------------------------	-------

CREATININE	1.00	0.7 - 1.2	mg/dL
METHOD : COLORIMETRIC			

BUN/CREAT RATIO	8.00	8.0 - 15.0

URIC ACID, SERUM			
URIC ACID	5.5	3.4 - 7.0	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY			

TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.4	6.0 - 8.0	g/dL
METHOD: COLORIMETRIC			

ALBUMIN, SERUM			
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD: COLORIMETRIC			

GLOBULIN			
GLOBULIN	2.8	2.0 - 3.5	g/dL

ELECTROLYTES (NA/K/CL), SERUM

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Bhinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 15 Of 22

Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax:







CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16 ABHA NO REPORTED :19/04/2024 15:04:20

	<u> </u>	i		
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units	
SODIUM, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	138	136 - 145	mmol/L	
POTASSIUM, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	4.49	3.5 - 5.1	mmol/L	
CHLORIDE, SERUM	100	98 - 107	mmol/L	
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis,hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.Priyal Chinchkhede, MD **Consultant Pathologist**

Bhinchkhede

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 16 Of 22



View Report



Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:









CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin wher there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease,high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels:-Double Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Phinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 17 Of 22

View Report

Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







Male

PATIENT NAME: ANKIT PRATAP SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : **0181XD000828**

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO : AGE/SEX :3

:

.

RECEIVED : 17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: MICROSCOPIC EXAMINATION

APPEARANCE CLEAR

METHOD: MICROSCOPIC EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 6.0 4.6 - 8.0

METHOD: METHYL RED & BROMOTHYMOL BLUE

SPECIFIC GRAVITY 1.015 1.003 - 1.035
PROTEIN NOT DETECTED NOT DETECTED

METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

GLUCOSE NOT DETECTED NOT DETECTED

METHOD : GLUCOSE OXIDASE / PEROXIDASE (GOD - POD) METHOD

KETONES NOT DETECTED NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NOT DETECTED

METHOD: STRIP TEST - DIAZONIUM SALT COUPLING

UROBILINOGEN NORMAL NORMAL

METHOD: CAFFEINE BENZOATE

NITRITE NOT DETECTED NOT DETECTED

METHOD: STRIP NAPHTHOETHYLENEDIAMINE HYDROCHOLORIDE, TATTANIC ACID

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

METHOD: STRIP HETROCYCLIC CARBOXYLIC ACID ESTER, DIAZONIUM SALT

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

MOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

1-2

O-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

EPITHELIAL CELLS 1-2 0-5 /HPF

METHOD: MICROSCOPIC EXAMINATION

Dr.Priyal Chinchkhede, MD Consultant Pathologist

Phinchkhede

Dr. Ushma Wartikar, MD Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani



Page 18 Of 22

View Details

View Repor



Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







Male

PATIENT NAME: ANKIT PRATAP SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : ANKIM130888181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 17/04/2024 09:48:16 DELHI ABHA NO REPORTED :19/04/2024 15:04:20 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

NOT DETECTED **CASTS**

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED BACTERIA

YEAST NOT DETECTED NOT DETECTED

Interpretation(s)

METHOD: MICROSCOPIC EXAMINATION

8800465156

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions			
Proteins	Inflammation or immune illnesses			
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind			
	of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary			
	tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either			
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by			
	genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or			
	bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,			
	interaction with Bence-Jones protein			
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal			
	diseases			
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous			
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl			
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of			
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice			

Bhinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 19 Of 22





Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India





REF. DOCTOR: SELF



PATIENT NAME: ANKIT PRATAP SINGH

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0181XD000828

PATIENT ID : ANKIM130888181

CLIENT PATIENT ID: ABHA NO : AGE/SEX : 35 Years

DRAWN :

RECEIVED :17/04/2024 09:48:16 REPORTED :19/04/2024 15:04:20

Test Report Status Final Results Biological Reference Interval Units

Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis



Dr.Priyal Chinchkhede, MD Consultant Pathologist Dr. Ushma Wartikar, MD Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head

Page 20 Of 22

View Details





Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax: CIN - U74899PB1995PLC045956







REF. DOCTOR: SELF **PATIENT NAME: ANKIT PRATAP SINGH**

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181XD000828

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

: ANKIM130888181

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 17/04/2024 09:48:16

:35 Years

REPORTED :19/04/2024 15:04:20

Test Report Status Results **Biological Reference Interval Final** Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

Т3	150.0	80 - 200	ng/dL
METHOD: ELECTROCHEMILUMINESCENCE			
T4	6.89	5.1 - 14.1	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	2.210	0.27 - 4.2	μIU/mL
METHOD: ELECTROCHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Phinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 21 Of 22



Agilus Diagnostics Ltd Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India



8800465156





PATIENT NAME: ANKIT PRATAP SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181XD000828 AGE/SEX :35 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : ANKIM130888181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 17/04/2024 09:48:16 DELHI ABHA NO REPORTED :19/04/2024 15:04:20 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units **Final**

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4. TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Bhinchkhede

Dr.Priyal Chinchkhede, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 22 Of 22

View Report





